陈明,郑博,彭红玉,王新刚,霍勇

• 1:北京大学第一医院心血管内科

摘要(Abstract)：

目的评价新型无载体西罗莫司药物洗脱支架(polymer-free sirolimus-eluting stent,PFSES)在小型猪冠状动脉模型中抑制新生内膜增殖的有效性和安全性。方法金属裸支架(baremental stent,BMS,n=13)、无载体纳米微孔裸支架(polymer-free bare mental stent,PFBMS,n=13)、聚合物载体西罗莫司洗脱支架(polymeribased sirolimus-eluting stent,PSES,n=13)以及PFSES(n=13)被分别随机置入26头小型猪的前降支(n=26)和回旋支(n=26)。支架置入28天和90天后,复查冠状动脉造影评价管腔丢失。90天后处死部分动物(n=12)行塑料包埋硬组织切片染色组织形态学分析。结果置入28天(n=24)及90天(n=12),PFSES与BMS相比,显著降低管腔丢失(0.69±0.49 mm比1.27±0.36 mm,P=0.041;0.77±0.44 mm比1.33±0.29 mm,P<0.01)。在90天组织形态学分析中,损伤积分相似的情况下,PFSES较BMS明显减少新生内膜面积(2.412±1.149 mm2比4.475±1.345 mm2,P<0.05)。PFSES炎症反应与BMS相似,且明显低于PSES。结论PFSES在置入小型猪冠状动脉28及90天后,可以安全有效地抑制内膜增殖和预防支架内再狭窄。

关键词(KeyWords)： 支架;西罗莫司;药物载体;冠状动脉再狭窄;猪,雏型

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈明,郑博,彭红玉,王新刚,霍勇

参考文献(References)：

• [1]Isenberg MJ.A hierarchical Bayesian meta-analysis of random-ised clinical trials of drug-eluting stents.Lancet,2004,364:583-591.
• [2]Sousa JE,Costa MA,Sousa AG,et al.Two-year angiographicand intravascular ultrasound follow-up after implantation of siroli-mus-eluting stents in human coronary arteries.Circulation,2003,107:381-383.
• [3]Morice MC,Serruys PW,Sousa JE,et al.A randomized com-parison of a sirolimus-eluting stent with a standard stent for coro-nary revascularization.N Engl J Med,2002,346:1773-1780.
• [4]Moses J,Leon MB,Popma JJ,et al.Sirolimus-eluting stentsversus standard stents in patients with stenosis in a native coro-nary artery.N Engl J Med,2003,349:1315-1323.
• [5]Stone GW,Ellis SG,CoxDA,et al.Apolymer-based,paclitax-el-eluting stent in patients with coronary artery disease.N Engl JMed,2004,350:221-231.
• [6]Virmani R,Guagliumi G,Farb A,et al.Localized hypersensitiv-ity and late coronary thrombosis secondary to a sirolimus-elutingstent:Should we be cautious?Circulation,2004,109:701-705.
• [7]Virmani R,Farb A,Guagliumi G,et al.Drug-eluting stents:Caution and concerns for Long-term outcome.Coron Artery Dis,2004,15:313-331.
• [8]McFadden EP,Stabile E,Regar E,et al.Late thrombosis indrug-eluting coronary stents after discontinuation of antiplatelettherapy.Lancet,2004,364:1519-1521.
• [9]Fernandez C,Hernandez R.Drug-eluting stent thrombosis:Re-sults from a pooled analysis including 10 randomized studies.JAm Coll Cardiol,2005,45;954-959.
• [10]Wessely R,Hausleiter J,Michaelis C,et al.Inhibition of neoin-tima for mation by a novel drug-eluting stent systemthat allows fordoseadjustable,multiple,and on-site stent coating.ArteriosclerThromb Vasc Biol,2005,25:748-753.
• [11]Schwartz RS,Huber KC,Murphy JG,et al.Restenosis and theproportional neointimal response to coronary artery injury:Resultsin a porcine model.J Am Coll Cardiol,1992,19:267-274.
• [12]Cilingiroglu M,Elliott J,Patel D,et al.Long-term effects of no-vel biolimus eluting DEVAX AXXESS plus nitinol self-expandingstent in a porcine coronary model.Cathet Cardiovasc Interv,2006,68:271-279.
• [13]Carter AJ,Aggarwal M,Kopia GA,et al.Long-term effects ofpolymer-based,slow-release,sirolimus-eluting stents in a porcinecoronary model.Cardiovasc Res,2004,63:617-624.
• [14]Virmani R,Kolodgie FD,Farb A.Drug-eluting stents:are theyreally safe?Am Heart Hosp J,2004,2:85-88.